2-8-2024 - Paths to - and from - Small Cell Lung Cancer

(1:3:35)

Dr Charles Rudin: Changing the Tide in Funding for Lung Cancer Research

(1:11)

Researcher comment: The KEYNOTE-604 trial | Charles Rudin

(5:2)

Lung Cancer Living Room: Advancements in Small Cell Lung Cancer - 12/14/21 - Unedited

(1:5:35)

Charles Rudin, MD, PhD, shares the take home message regarding Keynote-604 for lung cancer treatment

(46)

Dr. Charles Rudin: Changing the Tide in Lung Cancer Research Funding

(1:29)

Dr. Charles Rudin: Research Funding

(1:11)

Dr. Rudin on Caveats of the KEYNOTE-021 in Patients With NSCLC

(54)

Charles Rudin, MD, PhD, discusses the Keynote-604 study and the role of Keytruda in ES-SCLC

(53)

Small Cell Lung Cancer

(2:36)

SCLC: Are we witnessing any progress

(17:19)

GRACEcast-096_Lung-Cancer_MM in LC Pt 1: Dr. Charles Rudin on The Lung Cancer Mutation Consortium

(17:36)

Charles Rudin, MD, PhD, shares outcomes of the Keynote 604 study to investigating Keytruda and chemo

(2:47)

Charles M. Rudin, Maria Catherine Pietanza, Todd Michael Bauer, et. al.

(7:50)

Dr. Rudin on the Design of the KEYNOTE-604 Trial in ES-SCLC

(1:2)

Dr. Rudin on Expansion of Immunotherapy in Lung Cancer

(1:36)

Safety and efficacy of single agent rovalpituzumab tesirine in small cell lung cancer (SCLC)

(7:14)

Andrew Rudin and Charles Behlen on \

(17:55)